Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 14, 2021- New app will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data- NeuroSphere myPath will be available in the Apple App Store in the coming weeks and will be compatible with the latest iOS operating system- Jan 12, 2021- Abbott will complete the U.S. government order for 150 million BinaxNOW COVID-19 tests this week and will supply 30 million additional tests through March via a new government order- Company is in final stages of completing its self-funded capacity expansion across U.S. manufacturing sites- Abbott has the most advanced and comprehensive COVID-19 rapid test portfolio available today, including ID NOW, BinaxNOW, the BinaxNOW at-home test and the NAVICA app- Workplaces, universities, schools and other qualified organizations that need frequent and affordable testing can now directly procure BinaxNOW tests from Abbott
- Jan 11, 2021- The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott's i-STAT™ Alinity™ handheld device- Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%- The test simultaneously measures biomarkers UCH-L1 and GFAP, proteins found in the blood after a concussion or head trauma- Building on this initial clearance, Abbott is also working on a test that would use whole blood on i-STAT at the point of care, and developing a test for its Alinity™ i and ARCHITECT® core laboratory instruments under FDA breakthrough designation
- Dec 22, 2020- 88% of Americans say it's important for COVID-19 testing to work in support of vaccine rollout- Americans agree an authorized vaccine will not change the environment overnight, indicating a need for ongoing layered protections- Despite belief in effectiveness of vaccination and testing, there is concern that other precautionary measures will decline